Message from Frédéric Cren and Pierre Broqua, co-founders and managers of Inventiva
Thank you for your support and your confidence in our IPO which enabled us to raise more than €48 million. The IPO proceeds will allow to pursue the development of our various programs diseases with very strong medical needs such as NASH1systemic sclerosis or Maroteaux-Lamy syndrome (MPS VI).
“A well-known, major player in fibrosis”
Founded in Dijon in 2012,Inventiva aims to treat fibrosis - a major public health concern. This pathological hyper-scarring is responsible for close to half of the deaths occurring in developed countries2
Inventiva is developing new innovative therapies to treat fibrosis, thanks to its unique technology platform based on its extensive knowledge of the mechanisms of fibrosis and a compound library of over 240,000 molecules.
Our lead product Lanifibranor (IVA337) is in Phase IIb of clinical development in two indications: NASH, a severe fibrotic liver disease affecting over 30 million people in the United States3, and for which the worldwide potential market is estimated to between $35 billion and $40 billion4, as well as systemic sclerosis, an orphan disease with no known treatment affecting close to 170,000 patients worldwide and a potential market estimated to over €1 billion in the United States5. Lanifibranor’s Phase IIb headline results in NASH are expected mid-2018 and in the second half of 2018 for systemic sclerosis
“Our lead product Lanifibranor (IVA337) is in Phase IIb of clinical development in two indications: NASH and systemic sclerosis”
In parallel, we have entered into two strategic partnerships with renowned pharma groups such as AbbVie and BoehringerIngelheim. These two agreements have established Inventiva as a major player in fibrosis. For example, the milestone payments of the partnership with BoehringerIngelheim could amount to €170 million, excluding royalties. We have also developed a preclinical pipeline, which can potentially lead to future new partnerships.
« Two strategic partnerships with renowned pharma groups such as AbbVie and Boehringer Ingelheim »
Inventiva has over 90 highly qualified scientists and a solid financial position, allowing it to pursue the development of its clinical programs, whose first results are expected by mid-2018.
As you can imagine, we are excited to continue developing Inventiva with your support.
So, let’s discover together tomorrow’s fibrosis therapeutic options.
1 Non-Alcoholic StéatoHépatitis
2 The Journal of Clinical Investigation; Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases; March 2007.
3 Angulo et al. Hepatology 1999; 30(6):1356-62. ; Minervini et al. J Hepatology 2009; 50:501–510.
4 Étude de marché réalisée par la Deutsche Bank, 14 juillet 2014
5 Corbus Investor Presentation ; Cytori Therapeutics Investor Presentation